PAVmed Inc.

NasdaqCM:PAVM Stock Report

Market Cap: US$8.7m

PAVmed Management

Management criteria checks 3/4

PAVmed's CEO is Lishan Aklog, appointed in Jun 2014, has a tenure of 10.67 years. total yearly compensation is $953.20K, comprised of 95.8% salary and 4.2% bonuses, including company stock and options. directly owns 3.4% of the company’s shares, worth $296.90K. The average tenure of the management team and the board of directors is 2.4 years and 10.1 years respectively.

Key information

Lishan Aklog

Chief executive officer

US$953.2k

Total compensation

CEO salary percentage95.8%
CEO tenure10.7yrs
CEO ownership3.4%
Management average tenure2.4yrs
Board average tenure10.1yrs

Recent management updates

Recent updates

Are Investors Undervaluing PAVmed Inc. (NASDAQ:PAVM) By 28%?

Jan 29
Are Investors Undervaluing PAVmed Inc. (NASDAQ:PAVM) By 28%?

Is PAVmed (NASDAQ:PAVM) Using Debt In A Risky Way?

Aug 17
Is PAVmed (NASDAQ:PAVM) Using Debt In A Risky Way?

PAVmed Non-GAAP EPS of -$0.17 beats by $0.03

Aug 16

PAVmed Continues To Have Lots Of Potential But EsoGuard Determines Short-Term Progress

Jul 05

Start Accumulating PAVmed

Dec 24

We Think PAVmed (NASDAQ:PAVM) Can Afford To Drive Business Growth

Sep 02
We Think PAVmed (NASDAQ:PAVM) Can Afford To Drive Business Growth

PAVmed: Long Term Investment Case Remains Despite Weak Q2

Aug 23

PAVmed: A True Game-Changer For Medical Device Innovation

Jun 14

PAVmed forms digital health company, Veris Health

Jun 02

PAVmed's subsidiary receives CE mark for EsoCheck esophageal cell collection device

May 26

PAVmed (NASDAQ:PAVM) Is In A Good Position To Deliver On Growth Plans

May 19
PAVmed (NASDAQ:PAVM) Is In A Good Position To Deliver On Growth Plans

PAVmed drops 14% on launch of $13.4M direct offering

Jan 06

PAVmed closes additional direct offering of common stock

Dec 22

Do Institutions Own PAVmed Inc. (NASDAQ:PAVM) Shares?

Dec 16
Do Institutions Own PAVmed Inc. (NASDAQ:PAVM) Shares?

PAVmed offers stock for $8.9M

Dec 11

PAVmed EPS beats by $0.02

Nov 17

There Is Progress At PAVmed, But More Patience Is Required

Oct 30

CEO Compensation Analysis

How has Lishan Aklog's remuneration changed compared to PAVmed's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

US$15m

Jun 30 2024n/an/a

-US$67m

Mar 31 2024n/an/a

-US$71m

Dec 31 2023US$953kUS$913k

-US$66m

Sep 30 2023n/an/a

-US$71m

Jun 30 2023n/an/a

-US$79m

Mar 31 2023n/an/a

-US$90m

Dec 31 2022US$1mUS$901k

-US$89m

Sep 30 2022n/an/a

-US$86m

Jun 30 2022n/an/a

-US$72m

Mar 31 2022n/an/a

-US$58m

Dec 31 2021US$9mUS$583k

-US$51m

Sep 30 2021n/an/a

-US$42m

Jun 30 2021n/an/a

-US$35m

Mar 31 2021n/an/a

-US$30m

Dec 31 2020US$1mUS$431k

-US$35m

Sep 30 2020n/an/a

-US$32m

Jun 30 2020n/an/a

-US$30m

Mar 31 2020n/an/a

-US$28m

Dec 31 2019US$890kUS$431k

-US$17m

Sep 30 2019n/an/a

-US$17m

Jun 30 2019n/an/a

-US$17m

Mar 31 2019n/an/a

-US$19m

Dec 31 2018US$772kUS$346k

-US$19m

Compensation vs Market: Lishan's total compensation ($USD953.20K) is above average for companies of similar size in the US market ($USD632.75K).

Compensation vs Earnings: Lishan's compensation has been consistent with company performance over the past year.

CEO

Lishan Aklog (58 yo)

10.7yrs

Tenure

US$953,200

Compensation

Dr. Lishan Aklog, M.D., serves as Executive Chairman at Veris Health Inc. since April 2023. He served as Independent Director at ContraFect Corporation since June 14, 2020 until December 04, 2023. Dr. Aklo...

Leadership Team

NamePositionTenureCompensationOwnership
Lishan Aklog
Chairman & CEO10.7yrsUS$953.20k3.4%
$ 296.9k
Dennis McGrath
President & CFO7.9yrsUS$673.50k0.46%
$ 40.2k
Shaun O'Neill
Executive VP & COO3yrsUS$498.00k0.16%
$ 14.2k
Michael Gordon
Executive VP2.8yrsUS$710.50k0%
$ 0
Brian deGuzman
Executive VP1.8yrsUS$593.10kno data
Suman Verma
Senior VP of Molecular Genetics & Chief Scientific Officer2.1yrsno datano data
Deepika Lakhani
Senior VP2.1yrsno datano data
Victoria Lee
Senior VP & Chief Medical Officer2.1yrsno datano data

2.4yrs

Average Tenure

58yo

Average Age

Experienced Management: PAVM's management team is considered experienced (2.4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Lishan Aklog
Chairman & CEO10.7yrsUS$953.20k3.4%
$ 296.9k
Ronald Sparks
Independent Director10.1yrsUS$251.90k0.59%
$ 51.4k
Todd Rosengart
Member of Medical Advisory Board10.3yrsno datano data
Timothy Baxter
Independent Director3.7yrsUS$238.90k0.59%
$ 51.4k
Marc Gerdisch
Member of Medical Advisory Board10.3yrsno datano data
Philip Stieg
Member of Medical Advisory Board10.1yrsno datano data
Albert Chin
Member of Medical Advisory Board10.1yrsno datano data
Michael Glennon
Independent Vice Chairman10.3yrsUS$228.90k0.74%
$ 64.5k
Timothy Murphy
Member of Medical Advisory Board10.3yrsno datano data
Debra White
Independent Director3.8yrsUS$248.90k0.59%
$ 51.4k
Christopher Hartnick
Member of Medical Advisory Board8.3yrsno datano data
Daniel Engelman
Member of Medical Advisory Board7.3yrsno datano data

10.1yrs

Average Tenure

62yo

Average Age

Experienced Board: PAVM's board of directors are seasoned and experienced ( 10.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/16 20:19
End of Day Share Price 2025/02/14 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

PAVmed Inc. is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Edward WooAscendiant Capital Markets LLC
Raymond MyersBenchmark Company
Charles DuncanCantor Fitzgerald & Co.